PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
京都大学 === 新制・課程博士 === 博士(医学) === 甲第23568号 === 医博第4782号 === 新制||医||1054(附属図書館) === 京都大学大学院医学研究科医学専攻 === (主査)教授 武藤 学, 教授 小川 誠司, 教授 戸井 雅和 === 学位規則第4条第1項該当 === Doctor of Medical Science === Kyoto University === DFAM...
Main Author: | Yokoyama, Daiju |
---|---|
Other Authors: | 横山, 大受 |
Format: | Doctoral Thesis |
Language: | English |
Published: |
Kyoto University
2021
|
Subjects: | |
Online Access: | http://hdl.handle.net/2433/266666 |
Similar Items
-
PTEN loss is associated with a poor response to trastuzumab in HER2- overexpressing gastroesophageal adenocarcinoma
by: Deguchi, Yasunori
Published: (2017) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01) -
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
by: Davidson M, et al.
Published: (2016-11-01) -
Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01) -
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)